Inventiva S.A. (ETR:6IV)

Market Cap	1.01B +352.4%
Revenue (ttm)	16.97M -10.4%
Net Income	-311.07M
EPS	-3.53
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,290
Average Volume	3,129
Open	5.37
Previous Close	5.10
Day's Range	5.37 - 5.39
52-Week Range	3.15 - 6.28
Beta	n/a
RSI	58.88
Earnings Date	Mar 30, 2026

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-β, a pre-clinical program for th...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 84
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 6IV

Financial Performance

In 2024, Inventiva's revenue was 14.09 million, a decrease of -38.24% compared to the previous year's 22.82 million. Losses were -184.21 million, 66.8% more than in 2023.